Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease-Reference-Cited by-同舟云学术

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease

Published:2018-10-10 Issue:11 Volume:14 Page:1505-1521
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Shaw Leslie M.¹,Arias Jalayne²,Blennow Kaj³,Galasko Douglas⁴,Molinuevo Jose Luis⁵,Salloway Stephen⁶,Schindler Suzanne⁷,Carrillo Maria C.⁸,Hendrix James A.⁸,Ross April⁸,Illes Judit⁹,Ramus Courtney⁹,Fifer Sheila¹⁰

Affiliation:

1. Department of Pathology and Laboratory MedicinePerelman School of MedicineUniversity of PennsylvaniaPAUSA

2. Department of NeurologyUniversity of CaliforniaSan FranciscoCAUSA

3. Department of Psychiatry and NeurochemistryUniversity of GothenbergMolndalSweden

4. Department of NeuroscienceUniversity of CaliforniaSan DiegoCAUSA

5. Barcelonabeta Brain Research CenterBarcelonaSpain

6. Butler Hospital Memory and Aging ProgramThe Warren Alpert Medical School of Brown UniversityBrown UniversityProvidenceRIUSA

7. Department of NeurologyWashington University St. Louis

8. Alzheimer's AssociationChicagoILUSA

9. Avalere HealthWashingtonDCUSA

10. Fifer AssociatesSan FranciscoCAUSA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2018.07.220

Reference144 articles.

1. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

2. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

3. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid

4. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

5. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the EUROIMMUN automated chemiluminescence immunoassays for measurement of four core biomarkers for Alzheimer’s disease in cerebrospinal fluid;Practical Laboratory Medicine;2024-08

2. Predicting continuous amyloid PET values with CSF tau phosphorylation occupancies;Alzheimer's & Dementia;2024-07-23

3. A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer’s disease;Nature Aging;2024-07-15

4. Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals;Nature Communications;2024-07-02

5. Advances in blood biomarkers for Alzheimer disease (AD): A review;The Kaohsiung Journal of Medical Sciences;2024-06-18